Advanced Oncotherapy PLC (LON:AVO)

Advanced Oncotherapy PLC (LON:AVO)

Share Price
38.50 p
-0.5 (-1.28 %)
Market Cap
£77.17 m
Proactive Investors - Run By Investors For Investors

Advanced Oncotherapy PLC

Advanced Oncotherapy is a specialist developer and provider of a breakthrough proton therapy system, the LIGHT system, which is the result of 25 years of work at CERN and ADAM.

Our focus is on developing and supplying technologies to maximise the destructive effect of radiation on tumours whilst minimising damage to the patient's healthy tissues.

Advanced Oncotherapy plc operates...

Market: LSE:AVO
52-week High/Low: 57.00p / 33.00p
Sector: Health Care, Equipment & Services
Market Cap: £77.17 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Advanced Oncotherapy PLC

Advanced Oncotherapy PLC Timeline

In April, Advanced Oncotherapy PLC (LON:AVO) announced the appointment of Moataz Karmalawy as a chief commercial officer and president of the firm’s US arm. He joined from Varian Particle Therapy, where he served as general manager of the worldwide particle therapy business. Here, in his first interview since joining the...
AVO is developing a proton beam system that blasts cancer called LIGHT. The initials stand for Linac Image Guided Hadron Technology. The company’s kit is cheaper and smaller than the current units, which are almost prohibitively expensive

Advanced Oncotherapy on track

“We have exciting plans for the future commercialisation of the LIGHT system once completely developed, and our discussions with potential partners around the world are ongoing,” said chief executive Nicolas Serandour
Advanced Onco's LIGHT system has been designed to electronically control the fast delivery of protons to the tumour site. The company has developed a measurement system that measures the speed of the beam, which allows the system to measure the energy of each proton pulse
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use